-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BKXhkZ2FbT+R/zpQETc0G3TgSO65McXb/JmX3jSl2yh3f8gUd4KrxPeFdRnUAQeJ EZggdRE6+uOrlU8B1Gckyw== 0000875320-09-000097.txt : 20091119 0000875320-09-000097.hdr.sgml : 20091119 20091119145722 ACCESSION NUMBER: 0000875320-09-000097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091117 FILED AS OF DATE: 20091119 DATE AS OF CHANGE: 20091119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Lisa CENTRAL INDEX KEY: 0001349077 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 091195667 MAIL ADDRESS: STREET 1: 125 SPRING STREET CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2009-11-17 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001349077 Kelly Lisa C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, Human Resources Common Stock 2009-11-17 4 S 0 875 40.20 D 24980 D Common Stock 1127 I 401(k) Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $40.20 (range $39.85 to 40.44). Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Valerie L. Andrews, Attorney-In-Fact 2009-11-19 -----END PRIVACY-ENHANCED MESSAGE-----